LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 911

Search options

  1. Article ; Online: Unleashing the power of pooled and subgroup analyses in psychiatry.

    Correll, Christoph U

    International clinical psychopharmacology

    2022  Volume 37, Issue 5, Page(s) 223–224

    MeSH term(s) Humans ; Psychiatry
    Language English
    Publishing date 2022-07-14
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632837-4
    ISSN 1473-5857 ; 0268-1315
    ISSN (online) 1473-5857
    ISSN 0268-1315
    DOI 10.1097/YIC.0000000000000423
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: State of the Art of Diagnostics and Genetics in Huntington's Chorea: Response to Dr Lange.

    Gupta, Mayank / Correll, Christoph U

    The primary care companion for CNS disorders

    2023  Volume 25, Issue 2

    MeSH term(s) Humans ; Huntington Disease/diagnosis ; Huntington Disease/genetics
    Language English
    Publishing date 2023-03-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2675414-9
    ISSN 2155-7780 ; 2155-7780
    ISSN (online) 2155-7780
    ISSN 2155-7780
    DOI 10.4088/PCC.23lr03487a
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Pharmacologic Treatment of Schizophrenia Beyond Dopamine Receptor Blockade-Has Its Time Come Yet?

    Correll, Christoph U / Citrome, Leslie

    JAMA psychiatry

    2023  Volume 81, Issue 2, Page(s) 118–120

    MeSH term(s) Humans ; Antipsychotic Agents/therapeutic use ; Dopamine ; Receptors, Dopamine/therapeutic use ; Schizophrenia/drug therapy
    Chemical Substances Antipsychotic Agents ; Dopamine (VTD58H1Z2X) ; Receptors, Dopamine
    Language English
    Publishing date 2023-12-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2701203-7
    ISSN 2168-6238 ; 2168-622X
    ISSN (online) 2168-6238
    ISSN 2168-622X
    DOI 10.1001/jamapsychiatry.2023.4353
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Evidence-based clinical care and policy making for schizophrenia.

    Solmi, Marco / Correll, Christoph U

    Nature reviews. Neurology

    2023  Volume 19, Issue 11, Page(s) 643–644

    MeSH term(s) Humans ; Schizophrenia/diagnosis ; Schizophrenia/therapy ; Policy Making ; Health Policy ; Decision Making
    Language English
    Publishing date 2023-09-07
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 2491514-2
    ISSN 1759-4766 ; 1759-4758
    ISSN (online) 1759-4766
    ISSN 1759-4758
    DOI 10.1038/s41582-023-00872-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia.

    Meyer, Jonathan M / Correll, Christoph U

    CNS drugs

    2023  Volume 37, Issue 7, Page(s) 545–570

    Abstract: Patients with schizophrenia experience a broad range of detrimental health outcomes resulting from illness severity, heterogeneity of disease, lifestyle behaviors, and adverse effects of antipsychotics. Because of these various factors, patients with ... ...

    Abstract Patients with schizophrenia experience a broad range of detrimental health outcomes resulting from illness severity, heterogeneity of disease, lifestyle behaviors, and adverse effects of antipsychotics. Because of these various factors, patients with schizophrenia have a much higher risk of cardiometabolic abnormalities than people without psychiatric illness. Although exposure to many antipsychotics increases cardiometabolic risk factors, mortality is higher in patients who are not treated versus those who are treated with antipsychotics. This indicates both direct and indirect benefits of adequately treated illness, as well as the need for beneficial medications that result in fewer cardiometabolic risk factors and comorbidities. The aim of the current narrative review was to outline the association between cardiometabolic dysfunction and schizophrenia, as well as discuss the confluence of factors that increase cardiometabolic risk in this patient population. An increased understanding of the pathophysiology of schizophrenia has guided discovery of novel treatments that do not directly target dopamine and that not only do not add, but may potentially minimize relevant cardiometabolic burden for these patients. Key discoveries that have advanced the understanding of the neural circuitry and pathophysiology of schizophrenia now provide possible pathways toward the development of new and effective treatments that may mitigate the risk of metabolic dysfunction in these patients. Novel targets and preclinical and clinical data on emerging treatments, such as glycine transport inhibitors, nicotinic and muscarinic receptor agonists, and trace amine-associated receptor-1 agonists, offer promise toward relevant therapeutic advancements. Numerous areas of investigation currently exist with the potential to considerably progress our knowledge and treatment of schizophrenia.
    MeSH term(s) Humans ; Schizophrenia/drug therapy ; Schizophrenia/epidemiology ; Antipsychotic Agents/adverse effects ; Comorbidity ; Cardiovascular Diseases/chemically induced
    Chemical Substances Antipsychotic Agents
    Language English
    Publishing date 2023-07-20
    Publishing country New Zealand
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1203800-3
    ISSN 1179-1934 ; 1172-7047
    ISSN (online) 1179-1934
    ISSN 1172-7047
    DOI 10.1007/s40263-023-01022-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges.

    Haddad, Peter M / Correll, Christoph U

    Expert opinion on pharmacotherapy

    2023  Volume 24, Issue 4, Page(s) 473–493

    Abstract: Introduction: Maintenance antipsychotic treatment improves multiple outcomes in people with schizophrenia. These benefits are challenged by medication nonadherence, which is a common occurrence. Long-acting injectable antipsychotic (LAI) formulations ... ...

    Abstract Introduction: Maintenance antipsychotic treatment improves multiple outcomes in people with schizophrenia. These benefits are challenged by medication nonadherence, which is a common occurrence. Long-acting injectable antipsychotic (LAI) formulations were developed to reduce nonadherence and thereby improve outcomes. This narrative review is based on a PubMed search (January 2000 - August 2022) for studies on LAI antipsychotics.
    Areas covered: Opportunities and challenges associated with LAIs are reviewed. Advantages, compared to oral antipsychotics (OAs), include improved adherence, reduced relapse and hospitalization risk, delayed and lower relapse risk after stopping treatment, and the ability to differentiate true treatment resistance from 'pseudo'-resistance. Additionally, LAIs are associated with lower all-cause mortality than OAs. LAIs are under-used in many services, partly reflecting negative attitudes, misconceptions, and lack of knowledge among clinicians, patients, and carers. Practical barriers to LAI use include acquisition costs and inadequate service structures to administer/monitor LAI treatment.
    Expert opinion: The education and engagement of clinicians, patients and caregivers can assist more informed decision-making regarding LAIs. Future research regarding LAIs should encompass multiple complementary designs, focus on functionality and recovery outcomes, and include groups at high risk of relapse, including those with comorbid substance use disorders and early in the course of schizophrenia.
    MeSH term(s) Humans ; Antipsychotic Agents/adverse effects ; Schizophrenia/drug therapy ; Hospitalization ; Injections, Intramuscular ; Medication Adherence ; Delayed-Action Preparations ; Recurrence
    Chemical Substances Antipsychotic Agents ; Delayed-Action Preparations
    Language English
    Publishing date 2023-03-15
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2023.2181073
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches.

    Højlund, Mikkel / Correll, Christoph U

    Expert opinion on pharmacotherapy

    2023  Volume 24, Issue 13, Page(s) 1463–1489

    Abstract: Introduction: Long-acting injectable antipsychotics (LAIs) are an effective, but potentially underutilized treatment option in schizophrenia and other severe mental illnesses. Prescribing information typically focuses on how to initiate treatment from ... ...

    Abstract Introduction: Long-acting injectable antipsychotics (LAIs) are an effective, but potentially underutilized treatment option in schizophrenia and other severe mental illnesses. Prescribing information typically focuses on how to initiate treatment from the corresponding oral formulations. However, in clinical practice other scenarios, such as switching from other oral antipsychotics or other LAIs, occur frequently, requiring guidance.
    Areas covered: Pharmacodynamic properties of antipsychotics and their relation to rebound symptoms. Pharmacokinetic properties of LAIs and their implications for switching approaches. Specific approaches to switching to LAIs.
    Expert opinion: The LAI landscape has evolved significantly in the last decade with more formulations available, longer dosing intervals, and extended indications. However, currently available LAIs have various shortcomings, e.g. short dosing intervals, need for oral supplementation, loading regimens, deep intramuscular injection and/or restricted indications. Recent improvements include a one-day initiation option for aripiprazole lauroxil, aripiprazole monohydrate once-monthly, risperidone in situ microparticles and subcutaneous risperidone. Future LAI developments should focus on longer dosing intervals, subcutaneous administration, expansion of LAIs beyond currently available antipsychotic agents and indications beyond schizophrenia and bipolar disorder. In the future, LAIs might become a first-line treatment after initial oral stabilization for chronic mental disorders with need for maintenance treatment and presence of significant non-adherence.
    MeSH term(s) Humans ; Antipsychotic Agents/therapeutic use ; Risperidone/therapeutic use ; Schizophrenia/drug therapy ; Bipolar Disorder/drug therapy ; Injections, Intramuscular ; Delayed-Action Preparations
    Chemical Substances Antipsychotic Agents ; Risperidone (L6UH7ZF8HC) ; Delayed-Action Preparations
    Language English
    Publishing date 2023-06-27
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1080/14656566.2023.2228686
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Historical developments, hotspots, and trends in tardive dyskinesia research: a scientometric analysis of 54 years of publications.

    Baminiwatta, Anuradha / Correll, Christoph U

    Frontiers in psychiatry

    2023  Volume 14, Page(s) 1194222

    Abstract: ... and Zhang XY, Correll CU and Remington G in the last decade (2012-2021). The most prolific journal was ...

    Abstract Background: Since being recognized as an important drug-induced clinical entity during the 1960s, tardive dyskinesia (TD) has generated an extensive body of research seeking to understand its clinical characteristics, epidemiology, pathophysiology and management. Modern scientometric approaches allow interactive visualization of large bodies of literature to identify trends and hotspots within knowledge domains. This study thus aimed to provide a comprehensive scientometric review of the TD literature.
    Methods: Web of Science was searched for articles, reviews, editorials and letters with the term "tardive dyskinesia" in the title, abstract, or keywords through 12/31/2021. A total of 5,228 publications and 182,052 citations were included. Annual research output, prominent research areas, authors, affiliations and countries were summarized. VOSViewer and CiteSpace were used for bibliometric mapping and co-citation analysis. Structural and temporal metrics were used to identify key publications in the network.
    Results: TD-related publications peaked in the 1990s, gradually declined after 2004, and showed a further small increase after 2015. The most prolific authors were Kane JM, Lieberman JA, and Jeste DV overall (1968-2021), and Zhang XY, Correll CU and Remington G in the last decade (2012-2021). The most prolific journal was the Journal of Clinical Psychiatry overall, and the Journal of Psychopharmacology in the last decade. Knowledge clusters in the 1960-1970s dealt with clinical and pharmacological characterization of TD. In the 1980s, epidemiology, clinical TD assessment, cognitive dysfunction and animal models predominated. During the 1990s, research diverged into pathophysiological studies, especially oxidative stress, and clinical trials on atypical antipsychotics, with a focus on clozapine and bipolar disorder. In the 1990-2000s, pharmacogenetics emerged. More recent clusters include serotonergic receptors, dopamine-supersensitivity psychosis, primary motor abnormalities of schizophrenia, epidemiology/meta-analyses, and advances in TD treatment, particularly vesicular monoamine transporter-2 inhibitors since 2017.
    Conclusion: This scientometric review visualized the evolution of scientific knowledge on TD over more than five decades. These findings will be useful for researchers to find relevant literature when writing scientific articles, choosing appropriate journals, finding collaborators or mentors for research, and to understand the historical developments and emerging trends in TD research.
    Language English
    Publishing date 2023-06-02
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2564218-2
    ISSN 1664-0640
    ISSN 1664-0640
    DOI 10.3389/fpsyt.2023.1194222
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Clozapine in treatment-resistant schizophrenia: Reflections from the Hallmark US clinical trial and beyond.

    Kane, John M / Schoretsanitis, Georgios / Rubio, Jose M / Correll, Christoph U

    Schizophrenia research

    2024  

    Language English
    Publishing date 2024-01-29
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 639422-x
    ISSN 1573-2509 ; 0920-9964
    ISSN (online) 1573-2509
    ISSN 0920-9964
    DOI 10.1016/j.schres.2024.01.035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The antipsychotic paradox: Lessons regarding determinants of premature mortality.

    Solmi, Marco / Correll, Christoph U

    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

    2022  Volume 62, Page(s) 1–3

    MeSH term(s) Antipsychotic Agents ; Mortality ; Mortality, Premature ; Risk Factors
    Chemical Substances Antipsychotic Agents
    Language English
    Publishing date 2022-07-02
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1082947-7
    ISSN 1873-7862 ; 0924-977X
    ISSN (online) 1873-7862
    ISSN 0924-977X
    DOI 10.1016/j.euroneuro.2022.05.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top